AI assistant
Protara Therapeutics, Inc. — Director's Dealing 2022
Jan 5, 2022
34057_dirs_2022-01-05_e9076509-8d2d-45e4-890c-1f166545c702.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2022-01-03
Reporting Person: Davis Blaine (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-03 | Common Stock | A | 14100 | $0.00 | Acquired | 15581 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-03 | Stock Option (Right to Buy) | $6.90 | A | 84800 | Acquired | 2032-01-02 | Common Stock (84800) | Direct |
Footnotes
F1: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 3, 2022.
F2: 25% of the shares vest on the one year anniversary of January 3, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.